Dr. Alan Liss has over 35 years of successful experience in the areas of drug development and biotechnology. He has focused on establishing and maintaining high-quality pharmaceutical project management systems - directing teams of scientists and support staff to improve manufacturing quality and efficiency, and GXP regulatory compliance.
Dr. Liss retired in late 2014 as the Director of the Public Health and Security Action Team Program of the US Food and Drug Administration Commissioner’s Medical Countermeasures Initiative. Before that position, he organized the creation of the Regulatory and Quality Division of the Biomedical Advanced Research and Development Authority (BARDA) of the US Government’s Department of HHS/ASPR.
Dr. Liss founded GXP farma, LLC (www.GXPfarma.com), an independent consulting group that focuses on moving drug development programs forward. His team has created strategic quality and regulatory plans for drug and biologics development and a novel business tool-oriented approach to facilitate the execution of these plans. He has also developed a series of focused audits designed to support potential mergers and acquisitions as well as to prepare for inspections by regulatory authorities, and has developed a mentoring program to grow expertise within client organizations.
Dr. Liss has authored over 60 scientific publications and has presented numerous lectures on quality, regulatory, medical countermeasures, vaccines, and other specialty manufacturing issues both nationally and internationally.
Dr. Liss received a B.S. degree in Genetics from the University of California, Berkeley, and a Ph.D. in Microbiology and Immunology from the University of Rochester School of Medicine and Dentistry.
Tuesday, September 15, 2020
11:00 AM – 12:30 PM EDT